Lauriston S. Taylor lecture: The quest for therapeutic actinide chelators

Health Physics

Volumn 95, Issue 5, 2008, Pages 465-492

  Durbin, Patricia W ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Actinides; Chelation; National Council on Radiation Protection and Measurements; Review papers

Indexed keywords

1,2 HYDROXYPYRIDONONATE; 3 LI, 4 LI, 5 LI(ME 3,2 HYDROXYPYRIDONONATE); 3,4,3 LI(1,2 HYDROXYPYRIDONONATE); 3,4,3 LI(1,2 ME 3,2 HYDROXYPYRIDONONATE); 4 LI(1,2 HYDROXYPYRIDONONATE); 5 LIO(ME 3,2 HYDROXYPYRIDONONATE); ACTINIDE; BIDENTATE HYDROXYPYRIDINONATE; CALCIUM SODIUM 2 ETHYLENEDIAMINETETRAACETATE; CALCIUM SODIUM 3 DIETHYLENETRIAMINEPENTAACETATE; CHELATING AGENT; CYCLIC CATHECOLATE; DEFEROXAMINE; EDETATE DISODIUM; EDETIC ACID; ENTEROCHELIN; H(2,2)(1,2 HYDROXYPYRIDONONATE); HEXADENTATE TREN(ME 3,2 HYDROXYPYRIDONONATE); LINEAR CATECHOLATE; ME 3,2 HYDROXYPYRIDONONATE; OCTADENTATE (1,2 HYDROXYPYRIDONONATE); OCTADENTATE 4,4,4 LI(1,2 HYDROXYPYRIDONONATE); OCTADENTATE DIETHYLENETRIAMINEPENTAACETIC ACID; OCTADENTATE H(2,2)(ME 3,2 HYDROXYPYRIDONONATE); PENTETIC ACID; SIDEROPHORE; TETRADENTATE 5 LIO(ME 3,2 HYDROXYPYRIDONONATE); TIRON 2,3 DIHYDROXYBENZENE 1,5 SULFONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC SODIUM 3 DIETHYLENETRIAMINEPENTAACETATE; AMERICIUM; PHENOL DERIVATIVE; PLUTONIUM; URANIUM;

BINDING AFFINITY; BONE CANCER; CHELATION THERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BINDING; DRUG EXCRETION; DRUG MEGADOSE; DRUG STRUCTURE; HUMAN; IRON BINDING CAPACITY; IRON STORAGE; IRON TRANSPORT; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION HAZARD; RADIATION INJURY; RADIATION PROTECTION; RADIOACTIVE CONTAMINATION; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; TOXIC WASTE; URINARY EXCRETION; WASTE MANAGEMENT; ANIMAL; ARTICLE; CHEMISTRY; ISOLATION AND PURIFICATION; MOUSE;

MAMMALIA;

ACTINOID SERIES ELEMENTS; AMERICIUM; ANIMALS; CHELATING AGENTS; DEFEROXAMINE; EDETIC ACID; HUMANS; MICE; PENTETIC ACID; PHENOLS; PLUTONIUM; URANIUM;

EID: 56149084813     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000326345.41816.c2     Document Type: Conference Paper

References (285)

1. Ahrland S. Solution chemistry and kinetics of ionic reactions. In: Katz JJ, Seaborg GT, Morss LR, eds. The chemistry of the actinide elements. New York: Chapman and Hall; 1986: 1480-1546.
2. Allen RA, Neuman WF. Treatment of acute systemic uranium intoxication in rats with 2,3-dimercaptopropano1 (BAL). In: Voegtlin C, Hodge HC, eds. The pharmacology and toxicology of uranium compounds. New York: McGraw-Hill Book Co.; 1953: 2092-2100.
3. Ansoborlo E, Chiappini R, Moulin V. Speciation in the environment and in biological media. Clefs CEA 48:14 -18; 2003.
4. Archimbaud M, Hengé-Napoli M-H, Lilianbaum D, Deslorges M, Montagne C. Application of calixarenes for the decorporation of uranium: present limitations and further trends. Radiat Prot Dosim 53:327-330; 1994. (Pubitemid 24239688)
5. Aub JC. Efforts to enhance excretion of Ra and Pb. In: Rosenthal MW, ed. Experimental and clinical approaches to the treatment of poisoning with radioactive substances. Transcript of a meeting. Lemont, IL: Argonne National Laboratory; Report ANL-5584; 1956: 2-11.
6. Aub JC, Evans RD, Gallagher DM, Tibbets DM. Effects of treatment on radium and calcium metabolism in the human body. Ann Intern Med 11:1443-1463; 1938.
7. Bailly T, Burgada R. Nouvelle methode de synthese du 3,4,(1,2- HOPO) (1,5,10, 14-tetra(1-hydroxy-2-pyridone-6-yl) 1,5,10,14- tetraazatetradecane). Compt Rend Acad Sci Paris, Ser IIc:241- 245; 1998 (in French).
8. Bair WJ. Radionuclides in the body: meeting the challenge. Health Phys 73:423- 432; 1997.
9. Ballou JE. Preliminary evaluation of several chelating agents for plutonium removal. Health Phys 8:731-734; 1962.
10. Barker WR, Callaghan C, Hill L, Nobill D, Acred P, Harper PB, Sowa MA, Fletton RA. G1549, a new cyclic hydroxamic acid antibiotic, isolated from culture broth of Pseudomonas alcaligenes. J Antibiot 32:1096 -1103; 1979.
11. 2+. J Inorg Nucl Chem 27: 2397-2412; 1965.
12. Basinger MA, Jones MM. Tiron (sodium 4,5-dihydroxybenzene-1,3- disulfonate) as an antidote for acute uranium intoxication in mice. Res Commun Chem Pathol Pharm 34:351-358; 1981.
13. Basinger MA, Forti RL, Berka LT, Jones MM, Mitchell WM, Johnson JE, Gibbs SJ. Phenolic chelating agents as antidotes for acute uranyl acetate intoxication in mice. J Toxicol Environ Health 11:237-246; 1983.
14. Belyaev YuA. Effect of some complexions on plutonium removal in rats. In: Lebidinsky AV, Moskalev YuI, eds. Plutonium-239: its distribution, biological effects and accelerated elimination. [English translation, Alexandria, VA: Defense Documentation Center; AD-430440 (also FTD-TT- 63-559); 1963: 237-245.]
15. Belyaev YuA. Plutonium removal in rats given some complexions by mouth. In: Moskalev YuI, ed. Distribution, biological effects, and accelerated excretion of radioactive isotopes. [English translation, Washington, DC: U.S. Atomic Energy Commission Technical Information Center; AEC-tr- 7590; 1974: 356-360.]
16. Bensted JPM, Taylor DM, Sowby FD. Carcinogenic effects of americium 241 and plutonium 239 in the rat. Brit J Radiol 38:920 -925; 1965.
17. Bickel H, Hall GE, Keller-Schierlein W, Prelog V, Vischer V, Wettstein A. Stoffwechselprodukte von Actinomyceten. Ü ber die Konstitution von Ferrioxamine B. Helv Chim Acta 43:2129 -2138; 1960 (in German).
18. Bloom W. Histopathology of irradiation from external and internal sources. New York: McGraw-Hill Book Co.; 1948.
19. Breitenstein BD Jr, Palmer HE. Lifetime follow-up of the 1976 americium accident victim. Radiat Prot Dosim 26:317-322; 1989.
20. Bruenger FW, Atherton DR, Stevens W, Stover BJ. Interaction between blood constituents and some actinides. In: Research in radiobiology. Salt Lake City, UT: University of Utah College of Medicine; annual report COO-119-244; 1971: 212-227.
21. Bruenger FW, Kuswik-Rubiega G, Miller SC. Decorporation of aged americium deposits by oral administration of lipophilic polyamino polycarboxylic acids. J Med Chem 35:112-118; 1992.
22. Buldakov LA. The toxicology of neptunium 237. In: Moskalev YuI, Kalistratova VS, eds. Biological effects of radiation from external and internal sources. [English translation, Washington, DC: U.S. Atomic Energy Commission Technical Information Center; AEC-tr-7457; 1974: 322-329.]
23. Bulman RA. Some aspects of the bioinorganic chemistry of the actinides. Coord Chem Revs 31:221-250; 1980.
24. Bulman RA, Griffin RJ. Investigations into techniques for removing intracellular plutonium-II. Complexing agents bound to macromolecules. Health Phys 40:228 -231; 1981.
25. Bulman RA, Griffin RJ, Russell AT. An examination of some complexing agents for ability to remove intracellularly deposited plutonium. Health Phys 37:729 -734; 1979.
26. Burns JH. Structural chemistry. In: Katz JJ, Seaborg GT, Morss LR, eds. The chemistry of the actinide elements. New York: Chapman and Hall; 1986: 1417-1479.
27. Casey HW, McClellan RO, Clarke WJ, Bustad LK. Acute toxicity of neptunium-237 and its relationship to liver function in sheep. Health Phys 9:827- 834; 1963.
28. Catsch A. Die Wirkung einger Chelatbildner auf die acute Toxicität von Uranylnitrate. Klin Wochschr 37:657- 660; 1959 (in German).
29. Catsch A. Principles and trends in therapeutic removal of internally deposited radionuclides. Health Phys 8:725-730; 1962.
30. Catsch A. Radioactive metal mobilization in medicine. Springfield, IL: Charles C. Thomas; 1964.
31. Catsch A, Lê DK. Untersuchen über therapeutische Möglichkeiten bei vergiftungen mit radioaktiven Spaltprodukten: 1. Mitteilug: Der Einfluss von Chelatbildern auf das Verhalten von Radiocer im Saugetierorganismus. Strahlentherapie 104:494 -506; 1957 (in German).
32. Catsch A, Harmuth-Hoene AE, Havlicek F, Carpy S. Interaction between chelates and endogenous zinc. In: Kornberg, HA, Norwood WD. Diagnosis and treatment of deposited radionuclides. Amsterdam: Excepta Medica Foundation; 1968: 413-418.
33. Chaberek S, Martell AE. Organic sequestering agents. New York: John Wiley; 1959.
34. Chemische Fabrik Uetikon. Swiss patent 245,126; 1947.
35. Choppin GR, Jensen MP. Actinides in solution: complexation and kinetics. In: Morss LR, Edelstein NM, Fuger J, eds. The chemistry of the actinide and transactinide elements. Dordrecht: Springer; 2006: 2524-2621.
36. Copp DH, Greenberg DM, Hamilton JG, Chace MJ, Van Middlesworth L, Cuthbertson EM, Axelrod DM. The deposition of plutonium and certain fission products in bone as a decontamination problem. Chicago, IL: Metallurgical Laboratory; Report CH-3591; 1946.
37. Copp DH, Axelrod DM, Hamilton JG. The deposition of radioactive materials in bone as a potential health hazard. Am J Roentgenol Radium Therap 58:10 -16; 1947.
38. Dagirmanjian R, Maynard EA, Hodge HC. The effects of calcium disodium ethylenediaminetetra-acetate on uranium poisoning in rats. J Pharmacol Exptl Therap 117:20 -28; 1956.
39. Destombes C, Laroche P, Cazoulat A, Gérasimo P. Réduction de las fixation rénale de 1 uranium par acétazolamide: importance de 1élimination urinaire du bicarbonate. Ann Pharm Fr 57:387- 400; 1999 (in French). (Pubitemid 29446115)
40. Domingo JL, Ortega A, Llobet JM, Paternain JL, Corbella J. The effects of repeated parenteral administration of chelating agents on the distribution and excretion of uranium. Res Commun Chem Pathol Pharmacol 64:161-164; 1989. (Pubitemid 19123238)
41. Domingo JL, Ortega A, Llobet JM, Corbella J. Effectiveness of chelation therapy with time after acute uranium intoxication. Fund Appl Toxicol 14:88 -95; 1990. (Pubitemid 20097358)
42. Dounce AL. The mechanism of action of uranium compounds in the animal body. In: Voegtlin C, Hodge HC, eds. The pharmacology and toxicology of uranium compounds. New York: McGraw-Hill Book Co.; 1949: 951-991.
43. Dounce AL, Lan TH. The action of uranium on enzymes and proteins. In: Voegtlin C, Hodge HC, eds. Pharmacology and toxicology of uranium compounds. New York: McGraw- Hill Book Co.; 1949: 759-888.
44. Duffield JR, Taylor DM. The biochemistry of the actinides. In: Freeman AJ, Keller C, eds. Handbook on the physics and chemistry of the actinides, Vol.4. Amsterdam: North Holland; 1986: 129-157.
45. Duffield JR, Taylor DM, Proctor SA. The binding of plutonium to transferrin in the presence of tri-n-butyl phosphate or nitrate and its release by diethylenetriaminpentaacetate and the tetrameric catechoylamide ligand LICAM(C). Int J Nucl Med Biol 12:483- 487; 1986.
46. Durbin PW. Metabolism and biological effects of the transplutonium elements. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium, plutonium, transplutonic elements. New York: Springer-Verlag; 1973: 739-908.
47. Durbin PW. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, eds. The chemistry of the actinide and transactinide elements. Dordrecht: Springer; 2006: 3339-3440.
48. Durbin PW, Wrenn ME. Metabolism and effects of uranium in animals. In: Wrenn ME, ed. Proceedings of a conference on occupational health experience with uranium. Washington, DC: U.S. Energy Research and Development Administration; Report ERDA-93; 1975: 68-139.
49. Durbin PW, Jones ES, Raymond KN, Weitl FL. Removal of 238Pu(IV) from mice by sulfonated tetrameric catechoyl amides. Radiat Res 81:170 -187; 1980.
50. Durbin PW, Jeung N, Jones ES, Weitl FL, Raymond KN. Enhancement of 238Pu elimination from mice by poly(catechoyl)amide ligands. Radiat Res 99:85-105; 1984.
51. Durbin PW, Jeung N, Rodgers SJ, Turowski PN, Weitl FL, White DL, Raymond KN. Removal of 238Pu(IV) from mice by polycatecholate, -hydroxamate or -hydroxypyridinonate ligands. Radiat Prot Dosim 26:351-358; 1989a.
52. Durbin PW, White DL, Jeung N, Weitl FL, Uhlir LC, Jones ES, Bruenger FW, Raymond KN. Chelation of 238Pu(IV) in vivo by 3,4,3-LICAM(C): effects of ligand methylation and pH. Health Phys 56:839-855; 1989b.
53. Durbin PW, Kullgren B, Xu J, Raymond KN. In vivo chelation of Am(III), Pu(IV), Np(V), and U(VI) in mice by TREN- (Me-3,2-HOPO). Radiat Prot Dosim 53:305-309; 1994.
54. Durbin PW, Kullgren B, Xu J, Raymond KN. New agents for in vivo chelation of uranium(VI): efficacy and toxicity in mice of multidentate catecholate and hydroxypyridinonate ligands. Health Phys 72:865- 879; 1997.
55. Durbin PW, Kullgren B, Xu J, Raymond KN. Development of decorporation agents for the actinides. Radiat Prot Dosim 79:433- 443; 1998a.
56. Durbin PW, Kullgren B, Xu J, Raymond KN, Allen PG, Bucher JJ, Edelstein NM, Shuh DK. 237Np: oxidation state in vivo and chelation by multidentate catecholate and hydroxypyridinonate ligands. Health Phys 75:34 -50; 1998b.
57. Durbin PW, Kullgren B, Ebbe SN, Xu J, Raymond KN. Chelating agents for uranium(VI): 2. efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice. Health Phys 78:511-521; 2000a.
58. Durbin PW, Kullgren B, Xu J, Raymond KN. Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. Int J Radiat Biol 76:199 -214; 2000b.
59. Durbin PW, Kullgren B, Xu J, Raymond KN, Hengé-Napoli M-H, Bailly T, Burgada R. Octadentate hydroxypyridinonate (HOPO) ligands for plutonium(IV): pharmacokinetics and oral efficacy. Radiat Prot Dosim 105:503-508; 2003.
60. Evans RD. Radium poisoning: a review of present knowledge. Am J Public Health 23:1017-1023; 1933.
61. Evans RD. Protection of radium dial workers and radiologists from injury by radium. J Ind Hyg Toxicol 25:253-269; 1943.
62. Evans RD, Harris RS, Bunker JWM. Radium metabolism in rats, and the production of osteosarcoma by experimental radium poisoning. Am J Roentgenol Radium Therap 52: 353-373; 1944.
63. Fahey JA. Neptunium. In: Katz JJ, Seaborg GT, Morss LR. The chemistry of the actinide elements. New York: Chapman and Hall; 1986: 442-498.
64. Fink RM. Biological studies with polonium, radium and plutonium. New York: McGraw-Hill Book Co.; 1950.
65. Finkel MP. Relative biological effectiveness of radium and other alpha emitters in CF no.1 female mice. Proc Soc Exptl Biol Med 83:494-498; 1953.
66. Foreman H. Decontamination studies. In: Medical and Health Physics Quarterly Report. Berkeley, CA: University of California Radiation Laboratory; Report UCRL-683; 1950: 38-41.
67. Foreman H. The pharmacology of some useful chelating agents. In: Seven MJ, Johnson LA, eds. Metal-binding in medicine. Philadelphia, PA: JB Lippincott; 1960: 82-94.
68. Foreman H, Hamilton JG. The use of chelating agents for accelerating excretion of radionuclides. Berkeley, CA: University of California Radiation Laboratory; Report UCRL- 1351; 1951.
69. Fritsch P, Herbreteau D, Moutharou K, Lantenois G, Richard- LeNaour H, Grillon G, Hoffschir D, Poncy JL, Laurent A, Masse R. Comparative toxicity of 3,4,3-LIHOPO and DTPA in baboons. Radiat Prot Dosim 53:315-318; 1994.
70. Garrett TM, Cass ME, Raymond KN. Hydrogen bonding in catechoyl amides. J Coord Chem 25:241-253; 1992.
71. Geigy Chemical Co. U.S. patent 2 831 885; 1954.
72. Gérasimo P, Duserre C, Métivier H. Biological behavior of Pu administered to animals as Pu-standard LICAM(C) complex: therapeutical attempts to decrease Pu kidney burden. Human Toxicol 5:309 -318; 1986.
73. Gerber GE, Thomas RG. Guidebook for the treatment of accidental contamination of workers. Radiat Prot Dosim 41:1- 49; 1992.
74. Gilbert ES, Koshurnikova NA, Sokolnikov M, Khokhryakov VF, Miller S, Preston DL, Romanov SA, Shilnikova NS, Suslova KG, Vostrotin VV. Liver cancers in Mayak workers. Radiat Res 154:246 -252; 2000.
75. Gindler JE. Physical and chemical properties of uranium. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium, plutonium, transplutonic elements. New York: Springer-Verlag; 1973: 69-164.
76. Goel DP, Dutt RP, Singh RP. Potentiodetermination of stability constants of bivalent and rare earth metal complexes with 2,3-pyridinediol. J Inorg Nucl Chem 32:3119 -3122; 1970.
77. Gonzales AJ. Radiation protection in the aftermath of a terrorist attack involving exposure to ionizing radiation. Health Phys 89:418-446; 2005.
78. Gorden AEV, Xu J, Raymond KN, Durbin PW. Rational design of sequestering agents for plutonium and other actinides. Chem Rev 103:4207- 4282; 2003.
79. Gorden AEV, Shuh DK, Tiedmann BEF, Wilson RE, Xu J, Raymond KN. Sequestered plutonium: [Pu4{5-LIO(Me-3,2- HOPO}2]-the first structurally characterized plutonium hydroxypyridinonate complex. Chem Eur J 11:2842-2848; 2005.
80. Gray SA, Stradling GN, Pearce MJ, Wilson I, Moody JC, Burgada R, Durbin PW, Raymond KN. Removal of plutonium and americium from the rat using 3,4,3-LIHOPO and DTPA after simulated wound contamination: effect of delayed administration and mass of plutonium. Radiat Prot Dosim 53:319 -322; 1994.
81. Grenthe I, Drozdzynski J, Fujino T, Buck EC, Albrecht- Schmitt TE, Wolf SF. Uranium. In: Morss LR, Edelstein NM, Fuger J, Katz JJ, eds. The chemistry of the actinide and transactinide elements. Dordrecht: Springer; 2006: 253-698.
82. Guilmette RA, Muggenburg BA. Reducing the radiation dose from inhaled americium-241 using continuously administered DTPA therapy. Int J Radiat Biol 53:261-271; 1988.
83. Guilmette RA, Lindhorst PS, Hanlon LL. Interaction of Pu and Am with bone mineral in vitro. Radiat Prot Dosim 79:453- 458; 1998.
84. Guilmette RA, Hakimi R, Durbin PW, Xu J, Raymond KN. Competitive binding of Pu and Am with bone mineral and novel chelating agents. Radiat Prot Dosim 105:527-534; 2003. (Pubitemid 37161286)
85. Hacker BC. The dragon's tail: radiation safety in the Manhattan Project 1942-1946. Berkeley, CA: The University Press; 1987.
86. Hamilton JG. Metabolism of the fission products and the heaviest elements. Radiol 49:325-343; 1947.
87. Hamilton JG. The metabolic properties of plutonium and allied materials. In: Medical and Health Physics Divisions Quarterly Report. Berkeley, CA: University of California Radiation Laboratory; Report UCRL-480; 1949: 4-16.
88. Hamilton JG, Scott KG. Effect of calcium salt of Versene upon metabolism of plutonium in the rat. Proc Soc Exptl Biol Med 83:301-305; 1953.
89. Hardcastle KI, Botta M, Fasano M, Digillo G. Experimental evidence for a second coordination sphere water molecule in the hydration structure of YbDTPA-insights for a reassessment of the relaxing data of GdDTPA. Eur J Inorg Chem 5:971-977; 2000.
90. Harris WR, Carrano CJ, Cooper SR, Sofen SR, Avdeef AE, McArdle JV, Raymond KN. Stability constants and electrochemical behavior of ferric enterobactin and model complexes. J Am Chem Soc 101:6097- 6104; 1979.
91. Heller HJ, Geigy JR. Some aspects of chelation chemistry. In: Diagnosis and treatment of radioactive poisoning. Proceedings of a Conference, October 1962. Vienna: IAEA; 1963: 347-380.
92. Hengé-Napoli M-H, Archimbaud M, Ansoborlo E, Métivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. Int J Radiat Biol 68:389 -393; 1995.
93. Hengé-Napoli M-H, Ansoborlo E, Houpert P, Mirto H. Paquet F, Burgada R, Hodgson S, Stradling GN. Progress and trends in in vivo chelation of uranium. Radiat Prot Dosim 79:449-452; 1998.
94. Hengé-Napoli M-H, Ansoborlo E, Chazal V, Houpert P, Mirto H. Paquet F, Gourmelon P. Efficacy of ethane-1-hydroxy- 1,1-bisphosphonate (EHBP) for decorporation of uranium after intra-muscular contamination in rats. Int J Radiat Biol 75:1473-1477; 1999.
95. Hengé-Napoli M-H, Stradling GN, Taylor DM. Decorporation of radionuclides from the human body. Radiat Prot Dosim 87:5-57; 2000.
96. Hodge HC. Historical forward. In: Voegtlin C, Hodge HC, eds. Pharmacology and toxicology of uranium compounds. New York: McGraw-Hill Book Co.; 1949: 1-13.
97. Hodge HC. A history of uranium poisoning (1824 -1942). In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium, plutonium, transplutonic elements. New York: Springer-Verlag; 1973: 5-68.
98. Hodge HC, Maynard EA, Downs WE. Antidotal action of polyphosphates in uranium poisoning. J Pharmacol Exptl Therap 101:17-18; 1951.
99. Hodge HC, Stannard JN, Hursh JB. Uranium, plutonium, transplutonic elements. New York: Springer-Verlag; 1973.
100. Hummel W, Anderegg G, Rao L, Puigdomènech I, Tochiyama O. Chemical thermodynamics of compounds and complexes of U, Np, Pu, Am, Tc, Se, Ni, and Zr with selected organic ligands. Chemical thermodynamics Vol. 9. Amsterdam: Elsevier; 2005.
101. Inoue Y, Tochiyama O. Study of the complexes of Np(V) with organic ligands by solvent extraction with TTA and 1,10- phenanthrolene. Polyhedron 2:627- 630; 1983.
102. International Atomic Energy Agency. Diagnosis and treatment of radioactive poisoning. Proceedings of a Conference, October 1962. Vienna: IAEA; 1963.
103. International Atomic Energy Agency. Diagnosis and treatment of incorporated radionuclides. Proceedings of a Seminar. Vienna: IAEA; 1976.
104. International Commission on Radiological Protection. Report of ICRP Committee II on permissible dose for internal radiation. ICRP Publication 2. Health Phys 3:1-380; 1959.
105. International Commission on Radiological Protection. A review of the radiosensitivity of the tissues in bone. Oxford: Pergamon Press; ICRP Publication 11; 1967.
106. International Commission on Radiological Protection. The metabolism of compounds of plutonium and other actinides. Oxford: Pergamon Press; ICRP Publication 19; 1972.
107. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30, Part 1; Ann ICRP 2(3/4); 1979.
108. International Commission on Radiological Protection. Biological effects of inhaled radionuclides. Oxford: Pergamon Press; ICRP Publication 31; Ann ICRP 4(1/2); 1980a.
109. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30, Part 2; Ann ICRP 4(3/4); 1980b.
110. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30, Part 3; Ann ICRP 6(2/3); 1982.
111. International Commission on Radiological Protection. The metabolism of plutonium and related elements. Oxford: Pergamon Press; ICRP Publication 48; Ann ICRP 16(2/3); 1986.
112. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30, Part 4; Ann ICRP 19(4); 1988.
113. International Commission on Radiological Protection. Agedependent doses to members of the public from intakes of radionuclides. ICRP Publication 69; Part 3. Ingestion dose coefficients. Oxford: Pergamon Press; Ann ICRP 25(1); 1995a.
114. International Commission on Radiological Protection. Agedependent doses to members of the public from intakes of radionuclides. ICRP Publication 71, Part 4. Inhalation dose coefficients. Oxford: Pergamon Press; Ann ICRP 25(3/4); 1995b.
115. Ivannikov AT. Effect of 2-acetylamino-1,3,4-thiadiazole-5- sulfonamide on the elimination of uranium from the organism and on the course of acute uranium poisoning. In: Moskalev YuI, ed. Distribution and biological effects of radioactive isotopes. [English translation, Washington, DC: U.S. Atomic Energy Commission Technical Information Center; AEC-tr-6944; 1968: 678-687.]
116. James AC, Taylor DM. DTPA therapy for chelation of 239Pu in bone: the influence of bone remodeling. Health Phys 21:31- 39; 1971.
117. Jolley WP, Roesch D, Horne R, Anthony DS. Effects of injected actinium equilibrium mixture on rats and mice. Miamisburg, OH: Mound Laboratory; Report MLM-1057; 1955.
118. Kappel MJ, Nitsche H, Raymond KN. Complexation of plutonium and americium by catecholate ligands. Inorg Chem 24:605- 611; 1985.
119. Katz JJ, Seaborg GT, Morss LR. The chemistry of the actinide elements. New York: Chapman and Hall; 1986.
120. Katz JJ, Morss LR, Edelstein NM, Fuger J. Introduction. In: Morss LR, Edelstein NM, Fuger J, eds. The chemistry of the actinide and transactinide elements. Dordrecht, The Netherlands: Springer; 2006: 1-17.
121. Kawin B, Copp DH, Hamilton JG. Studies of the metabolism of certain fission products and plutonium. Berkeley, CA: University of California Radiation Laboratory; Report UCRL-812; 1950.
122. Kornberg HA, Norwood WD. Diagnosis and treatment of deposited radionuclides. Amsterdam: Excerpta Medica Foundation; 1968.
123. Koshurnikova NA, Gilbert ES, Sokolnikov VF, Khokhryakov VR, Miller S, Preston DL, Romanov SA, Shilnikova NS, Suslova KG, Vostrotin VV. Bone cancers in Mayak workers. Radiat Res 154:237-245; 2000.
124. Kreisheimer M, Koshurnikova NA, Nekolla E, Khokhryakov VF, Romanow SA, Sokolnikov ME, Shilnikova NS, Okatenko PV, Kellerer AM. Lung cancer mortality among male nuclear workers of the Mayak facilities in the former Soviet Union. Radiat Res 154:3-11; 2000. (Pubitemid 30436502)
125. Kroll H. Development of chelating agents potentially more effective than EDTA in radioelement removal. In: Rosenthal MW, ed. Experimental and clinical approaches to the treatment of poisoning with radioactive substances. Transcript of a meeting. Lemont, IL: Argonne National Laboratory; Report ANL-5584; 1956: 150-151.
126. Kroll H, Korman S, Hart HE, Rosoff B, Spencer H, Laszlo D. Excretion of yttrium and lanthanum chelates of cyclohexane 1,2-transdiamine tetracetic acid and diethylenetriaminepentaacetic acid in man. Nature 180:919 -920; 1957.
127. Leach LJ, Yuile CL, Hodge HC, Sylvester GE, Wilson HB. A five-year inhalation study with natural uranium dioxide (UO2) dust. II. Post exposure retention and biological effects in the monkey, dog, and rat. Health Phys 25:239- 258; 1973.
128. Leong J, Neilands JB, Raymond KN. Coordination isomers of biological iron transport compounds. III. (1) Transport of a-cis-chromic desferrichrome by Ustilago sphaerogena. Biochem Biophys Res Commun 60:1066 -1071; 1974.
129. Levdik TI, Lemberg VK. Remote after effects of damage by neptunium-237. In: Moskalev YuI, ed. Remote after effects of radiation damage. [English translation, Washington, DC: U.S. Atomic Energy Commission Technical Information Center; AEC-tr-7387; 1972: 495-502.]
130. Levdik TI, Lemberg VK, Buldakov LA, Lyubchanskii ER, Pesternikov VM. Biological effectiveness of 237Np. Health Phys 22:643- 647; 1972.
131. Lisco H, Finkel MP, Brues AM. Carcinogenic properties of radioactive fission products and plutonium. Radiol 49:361- 363; 1947.
132. Lloyd RD, McFarland SS, Taylor GN, Williams JL, Mays CW. Decorporation of 241Am in beagles by DTPA. Radiat Res 62:97-106; 1975.
133. Lloyd RD, Bruenger FW, Mays CW, Atherton DR, Jones CW, Taylor GN, Stevens W, Durbin PW, Jeung N, Jones ES, Kappel MJ, Raymond KN, Weitl FL. Removal of Pu and Am from beagles and mice by 3,4,3-LICAM(C) and 3,4,3- LICAM(S). Radiat Res 99:106 -128; 1984.
134. Lloyd RD, Taylor GN, Mays CW. 241Am removal by DTPA vs. occurrence of skeletal malignancy. Health Phys 75:640- 645; 1998.
135. Lushbaugh CC, Washburn LC. FDA IND approval for Zn- DTPA, new clinical agent for decorporation therapy of actinides. Health Phys 36:472; 1979.
136. Lusky LM, Braun HA. Sodium catechol disulfonate protection in experimental uranium nitrate poisoning [abstract]. Fed Proc 9:297; 1950.
137. Lyubchanskii ER, Levdik TI. Neptunium 237 metabolism after inhalation thereof. In: Moskalev YuI, ed. Biological effects of radiation from external and internal sources. [English translation, Washington, DC: U.S. Atomic Energy Commission Technical Information Center; AEC-tr-7457; 1974: 309-321.]
138. Mack RC. Essentials of statistics for scientists and technologists. New York: Plenum Press; 1967.
139. Mahlum DD, Clarke WJ. 237Np toxicity in the rat. 1. Histopathologic and chemical observations in liver and kidneys. Health Phys 12:7-13; 1966.
140. Martell AE. The relationship of chemical structure to metalbinding action. In: Seven MJ, Johnson LA, eds. Metal binding in medicine. Philadelphia, PA: JB Lippincott Co.; 1960: 1-18.
141. Martell AE, Calvin M. Chemistry of the metal chelate compounds. New York, NY: Prentice-Hall; 1952.
142. Martell AE, Smith RM. Critical stability constants. Vol.3. Other organic ligands. New York: Plenum Press; 1977.
143. Matzanke BF, Muller-Matzanke G, Raymond KN. Siderophore-mediated iron transport. In: Loehr TM, ed. Iron carriers and iron proteins. New York, NY: VCH Publishers; 1989.
144. Mays CW, Taylor GN, Lloyd RD, Wrenn ME. Status of chelation research: a review. In: Wrenn ME, ed. Actinides in man and animals. Salt Lake City, UT: University of Utah, RD Press; 1981: 351-368.
145. Megirian R. The metabolic fate of synthetic metaphosphates and their influence on uranium excretion. Rochester, NY: University of Rochester; Report UR-281; 1953.
146. Métivier H, Masse R, Durbin PW, Raymond KN. Promotion by tetrameric catechoylamide ligands and CaNa3-DTPA of the dissociation in vitro of the Pu-transferrin complex formed after intravenous injection of Pu-tri-N-butyl-phosphate. Health Phys 49:1302-1305; 1985a.
147. Métivier H, Gerasimo P, Fritsch P, Masse R. Comparison of the efficacies of LICAMC and DTPA for the decorporation of plutonium-239 inhaled by baboons as a tributyl phosphate complex. In: Maisin JR, ed. EULEP Newsletter No. 40. Mol: European Late Effects Group CEN/SCK; 1985b: 23-25.
148. Meyer JM, Hohnadel D, Halle F. Cepabactin from Pseudomonas depacia, a new type of siderophore. J Gen Microbiol 135:1479 -1487; 1989.
149. Miller SC, Bruenger FW, Kuswik-Rabiega G, Liu G, Lloyd RD. Duration and dose-related effects of an orally administered, partially lipophilic polyaminopolycarboxylic acid on the decorporation of plutonium and americium. J Pharmacol Exptl Therap 267:548 -554; 1993. (Pubitemid 23325050)
150. Miller SC, Liu G, Bruenger FW, Lloyd RD. Efficacy of orally administered amphipathic polyaminopolycarboxylic acid chelators for the removal of plutonium and americium: comparison with injected Zn-DTPA in the rat. Radiat Prot Dosim 118:412- 420; 2006. (Pubitemid 44313431)
151. Morin M, Skupinski W, Nénot JC, Lafuma J. Experimental research on the treatment of contamination by actinide solutions. In: Bujdoso E, ed. Health physics problems of internal contamination. Budapest: Akademiai Kiado; 1973a: 317-1230
152. Morin M, Nénot JC, Lafuma J. The behavior of 237Np in the rat. Health Phys 24:311-315; 1973b.
153. Morss LR, Edelstein NM, Fuger J. The chemistry of the actinide and transactinide elements. Dordrecht: Springer; 2006.
154. Moskalev YuI. The toxicology and radiobiology of neptunium- 237. [English translation, Oak Ridge, TN: Oak Ridge National Laboratory; ORNL-tr-4936; 1979.]
155. Moskvin AI. Correlation of the stability constants of complexes of the actinides with the properties of the metal ions and ligands forming them. [English translation, New York: Plenum Corp.; Soviet Radiochem 13:230 -238; 1971.]
156. National Bureau of Standards. X-ray protection. Washington, DC: National Bureau of Standards; NBS Handbook 15; May 1931.
157. National Bureau of Standards. X-ray protection. Washington, DC: National Bureau of Standards; NBS Handbook 20; July 1936.
158. National Bureau of Standards. Safe handling of luminous compounds. Washington, DC: National Bureau of Standards; NBS Handbook 27; May 1941.
159. National Council on Radiation Protection and Measurements. Management of persons accidentally contaminated with radionuclides. Bethesda, MD: NCRP; NCRP Report No. 65; 1980.
160. National Council on Radiation Protection and Measurements. Neptunium: radiation guidelines. Bethesda, MD: NCRP; NCRP Report No. 90; 1988.
161. National Council on Radiation Protection and Measurements. Liver cancer risk from internally deposited radionuclides. Bethesda, MD: NCRP; NCRP Report No. 135; 2001.
162. Neilands JB. A crystalline organo-iron pigment from a rust fungus (Ustiago sphaerogena). J Am Chem Soc 74:4846- 4847; 1952.
163. Nénot JC, Stather JW. The toxicity of plutonium, americium, and curium. Oxford: Pergamon Press; 1979.
164. Nénot JC, Masse R, Morin M, Lafuma J. An experimental comparative study of the behavior of 237Np, 238Pu, 239Pu, 241Am and 242Cm in bone. Health Phys 22:657- 665; 1972.
165. Neuman WF, Neuman MW. The chemical dynamics of bone mineral. Chicago, IL: University of Chicago Press; 1958.
166. Nigrovic V, Catsch A. Dekorporation von Radionukliden (Vergleichende Untersuchungen an Desferrioxamine B und Diäthylenetriaminpentalssigsa ̈ure). Strahlentherapie 128:283-286; 1965 (in German).
167. O'Brien IG, Gibson F. The structure of enterochelin and related 2,3-dihydroxy-N-benzoylserine conjugates from Escherica coli. Biochim Biophys Acta 215:393- 402; 1970.
168. Ortega A, Domingo JL, Gomez M, Corbella J. Treatment of experimental acute uranium poisoning by chelating agents. Pharmacol Toxicol 64:247-251; 1989. (Pubitemid 19082331)
169. Painter E, Russell E, Prosser CL, Swift MN, Kisieleski W, Sacher G. Clinical physiology of dogs injected with plutonium. Effect of oral and intravenous sodium citrate and intravenous hypertonic saline on plutonium excretion. Oak Ridge, TN: U.S. Atomic Energy Commission; Report AECD-2042; 1946: 50-52.
170. Paquet F, Poncy J-L, Rateau G, Burgada R, Bailly T, Leroux Y, Raymond KN, Durbin PW, Masse R. Reduction of the retention of 238Pu inhaled as the tributylphosphate complex in rats treated by 3,4,(1,2-HOPO). Radiat Prot Dosim 53:323-326; 1994.
171. Paquet F, Poncy J-L, Métivier H, Grillon G, Fritsch P, Burgada R, Bailly T, Raymond KN, Durbin PW. Efficacy of 3,4,3- LI(1,2-HOPO) for enhancing the excretion of plutonium from rat after simulated wound contamination as a tri-butyl- N-phosphate complex. Int J Radiat Biol 68:663- 668; 1995a.
172. Paquet F, Verry M, Grillon G, Landesman C, Masse R, Taylor DM. Subcellular and intranuclear localization of neptunium-237(V) in rat liver. Radiat Res 143:214 -218; 1995b.
173. Paquet F, Ramounet B, Métivier H, Taylor DM. The effect of mass and initial chemical form of neptunium of its molecular associations in blood and liver. Radiat Res 146:306- 312; 1996. (Pubitemid 26320095)
174. Paquet F, Métivier H, Poncy J-L, Burgada R, Bailly T. Evaluation of the efficiency of DTPA and other new chelating agents for removing neptunium from target organs. Int J Radiat Biol 71:613- 621; 1997. (Pubitemid 27229758)
175. Paquet F, Ramounet B, Hengé-Napoli M-H, Métivier H, Gourmelon P. In vitro experiments to determine the mechanisms by which chelators remove neptunium and uranium from the body. Radiat Prot Dosim 79:467- 470; 1998.
176. Paquet F, Montègue B, Ansoborlo E, Hengé-Napoli M-H, Houpert P, Durbin PW, Raymond KN. Efficacy of 3,4,3- LIHOPO for reducing neptunium retention in the rat after simulated wound contamination. Int J Radiat Biol 76:113- 117; 2000.
177. Paquet F, Chazel V, Houpert P, Guilmette R, Muggenburg B. Efficacy of 3,4,(1,2-HOPO) for decorporation of Pu, Am, and U from rats injected intramuscularly with highfired particles of MOX. Radiat Prot Dosim 105:521-525; 2003.
178. Peter E, Volf V. Efficiency of Puchel, a lipophilic derivative of DTPA, in removing thorium from the rat. Health Phys 40:753-755; 1981. (Pubitemid 11112832)
179. Peters G, Keberle H, Schmidt K, Brunner H. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and rat. Biochem Pharmacol 15:93-109; 1966.
180. Piskunov EM, Rykov AG. Investigation of complex formation with diethylenetriaminepentaacetic acid. Soviet Radiochem 14:345-346; 1972.
181. Polig E. Topographic analysis of the microdistribution of 241Am in the rat femur as influenced by DTPA treatment. Radiat Res 67:128 -141; 1976.
182. Poncy J-L, Rateau G, Burgada R, Bailly T, Leroux Y, Raymond KN, Durbin PW, Masse R. Efficacy of 3,4,3-LIHOPO for reducing the retention of 238Pu in the rat after inhalation of the tributyl phosphate complex. Int J Radiat Biol 64:431- 436; 1993.
183. Popovici A, Geschickter CF, Reinovsky A, Rubin M. Experimental control of serum calcium levels in vivo. Proc Soc Exptl Biol Med 74:415- 417; 1950.
184. Ramounet B, Matton S, Grillon G, Fritsch P. Early biokinetics of actinides after intravenous administration of soluble forms of Pu(IV), Np(IV) and Np(V). J Alloys Compounds 271-273:103-105; 1998. (Pubitemid 128424926)
185. Ramounet-Le Gall B, Grillon G, Rateau G, Burgada R, Bailly T, Fritsch P. Comparative decorporation efficacy of 3,4,3- LIHOPO, 4,4,4-LIHOPO and DTPA after contamination of rats with soluble forms of 238Pu and 233U. Radiat Prot Dosim 105:535-538; 2003.
186. Raymond KN. Kinetically inert complexes of the siderophores in studies of microbial iron transport. In: Raymond KN, ed. Advances in chemistry series No. 162. Washington, DC: American Chemical Society; 1977: 33-54.
187. Raymond KN, Carrano CJ. Coordination chemistry and microbial iron transport. Acc Chem Res 12:183-190; 1979.
188. Raymond KN, Smith WL. Actinide sequestering agents and decontamination applications. Structure Bond 43:159 -185; 1981.
189. Raymond KN, Xu J. Siderophore-based hydroxypyridinonate sequestering agents. In: Bergeron RJ, Brittenham GN, eds. The development of iron chelators for clinical use. Boca Raton, FL: CRC Press; 1994: 307-327.
190. Rencova J, Volf V, Burgada R. Chelation therapy of thorium deposited in rat lung. Radiat Prot Dosim 75:459-462; 1998.
191. Riley PE, Abu-Dari K, Raymond KN. Synthesis of metal complexes of 1-hydroxy-2-pyridinone and the crystal structure of tetrakis (1-oxy-2-pyridinato) aquothorium(IV) dehydrate. Inorg Chem 22:3940 -3944; 1983.
192. Rosenthal MW. Experimental and clinical approaches to the treatment of poisoning with radioactive substances. Transcript of a meeting. Lemont, IL: Argonne National Laboratory; Report ANL-5584; 1956.
193. Rosenthal MW. Radioisotope absorption and methods of elimination: factors influencing elimination from the body. In: Caldecott RS, Snyder LA, eds. Radioisotopes in the biosphere. Minneapolis, MN: Minnesota Center for Continuing Study; 1960: 541-563.
194. Rosenthal MW, Lindenbaum A. Effect of desferrioxamine B-methane sulfonate (DFOM) on removal of plutonium in vitro and in vivo. Proc Soc Exptl Biol Med 117:749 -750; 1964.
195. Rosenthal MW, Lindenbaum A. Osteosarcoma as related to tissue distribution of monomeric and polymeric plutonium in mice. In: Mays CW, Jee WSS, eds. Delayed effects of bone-seeking radionuclides. Salt Lake City, UT: University of Utah Press; 1969: 371-386.
196. Rothstein A, Meier RC. The relationship of the cell surface to metabolism. VI. The chemical nature of uraniumcomplexing groups of the cell surface. J Cell Comp Physiol 38:245-270; 1951.
197. Scarrow RC. Hydroxypyridinones: ligands with high affinity and specificity for iron(III). Berkeley, CA: University of California; 1985. Thesis.
198. Scarrow RC, Riley PE, Abu-Dari K, White DL, Raymond KN. Synthesis, structures, and thermodynamics of complexation of cobalt(III) and iron(III) tris complexes of several chelating hydroxypyridinones. Inorg Chem 24:954 -967; 1985a.
199. Scarrow RC, White DL, Raymond KN. 1-hydroxy-2(1H)- pyridinone complexes: properties and structure of a novel Fe-Fe dimer. J Am Chem Soc 107:6540-6546; 1985b.
200. Schmidt H, Winthrop Chemical Co. U.S. patent 1718492; 1929.
201. Schubert J. Removal of radioelements from the mammalian body. Ann Rev Nucl Sci 5:369-412; 1955.
202. Schwarzenbach G, Ackerman H. Complexons V. Ethylencdiaminetetraacetic acid dissociation curve. Helv Chim Acta 30:1798 -1804; 1947.
203. Scott KG, Crowley J, Foreman H. Tracer studies: the metabolism of the fission products. In: Medical and Health Physics Divisions Quarterly Report. Berkeley, CA: University of California Radiation Laboratory; Report UCRL-587; 1950: 8-22.
204. Seaborg GT. Electronic structure of the heaviest elements. In: Seaborg GT, Katz JJ, Manning WM, eds. The transuranium elements. New York: McGraw-Hill Book Co.; 1949: 1492-1524.
205. Seaborg GT, Katz JJ. The actinide elements. New York: McGraw-Hill Book Co.; 1954.
206. Seidel A, Wiener M, Krüger E, Wirth R, Haffner H. Studies on the lysosomal binding of 141Ce, 239Np, 239Pu, and 241Am in rat and Syrian hamster liver using carrier-free electrophoresis. Nucl Med Biol 13:515-518; 1986.
207. Sephton-Smith R. Chelating agents in the diagnosis and treatment of iron overload in thalassemia. Ann NY Acad Sci 119:776 -778; 1964.
208. Seven MJ, Johnson LA. Metal binding in medicine. Philadelphia, PA: JB Lippincott Co.; 1960.
209. Shannon RD. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallographica A32, Part 5:751-767; 1976.
210. Sillen LG, Martell AE. Stability constants of metal-ion complexes. London: Chemical Society of London; Special Pub. 17; 1964.
211. Sillen LG, Martell AE. Stability constants of metal-ion complexes. Suppl. No.1. London: The Chemical Society London; Special Publication No. 25; 1971.
212. Singer TP, Muntz JA, Meyer J, Gasvoda B, Guzman-Barron ES. The reversible inhibition of enzymes by uranium. In: Tannenbaum A, ed. Toxicology of uranium. New York: McGraw-Hill Book Co.; 1951: 208-245.
213. 4+ with complexones and oxygen donor ligands. Indian J Chem 29A:822-824; 1990.
214. Smith RM, Martell AE. Critical stability constants. Vol.5, first supplement. New York: Plenum Press; 1982.
215. Smith RM, Martell AE. Critical stability constants. Vol.6, second supplement. New York: Plenum Press; 1989.
216. Smith VH. Removal of internally deposited plutonium. Nature 181:1792-1793; 1958.
217. Smith VH. The removal of internally deposited plutonium. In: Hanford Biology Research Annual Report for 1958. Richland, WA: Hanford Atomic Products; Operation Report HW-59500; 1959: 63-72.
218. Smith VH. Prevention of plutonium and neptunium deposition. In: Hanford Biology Research Annual Report for 1962. Richland, WA: Hanford Laboratory; Report HW-76000; 1963: 143-148.
219. Smith VH. Interactions in the metabolism of Pu239 and Np239. In: Hanford Biology Research Annual Report for 1963. Richland, WA: Hanford Atomic Products; Operation Report HW-80500; 1964: 73-75.
220. Smith VH. Therapeutic removal of internally deposited transuranium elements. Health Phys 22:765-778; 1972.
221. Smith WL, Raymond KN. Synthetic and structural chemistry of tetrakis(N-alkylalkanehydroxamato) thorium(IV) complexes. J Am Chem Soc 103:3341-3349; 1981.
222. Smyth HD. Atomic energy for military purposes. Princeton, NJ: Princeton University Press; 1945.
223. Sofen SR, Abu-Dari K, Freyberg DP, Raymond KN. A ligand field effect in the crystal and molecular structures of tetrakis(catecholato)uranate(IV) and -thorate(IV). J Am Chem Soc 100:7882-7887; 1978.
224. Stannard JN. Radioactivity and health: a history. Springfield, VA: National Technical Information Service; DOE/RL/ 01830-T59; 1988: 1575-1702.
225. Stannard JN. Radiation protection and the internal emitter saga. The Lauriston S. Taylor Lecture Series on Radiation Protection and Measurements Lecture No. 14. Bethesda, MD: National Council on Radiation Protection and Measurements; 1990.
226. Stather JW, Stradling GN, Smith H, Payne S, James AC, Strong JC, Ham S, Sumner S, Bulman RA, Hodgson A, Towndrow C, Ellender M. Decorporation of 238PuO2 from the hamster by inhalation of chelating agents. Health Phys 42:520 -525; 1982.
227. Stevens W, Bruenger FW, Atherton DR, Smith JM, Taylor GN. The distribution and retention of hexavalent 233U in the beagle. Radiat Res 83:109 -126; 1980. (Pubitemid 10081905)
228. Stone RS. Industrial medicine on the plutonium project. New York: McGraw-Hill Book Co.; 1951.
229. Stradling GN. Recent progress in decorporation of plutonium, americium and thorium. Radiat Prot Dosim 53:297-304; 1994.
230. Stradling GN. Decorporation of actinides: a review of recent research. J Alloys Compounds 271-273:72-77; 1998.
231. Stradling GN, Bulman RA. Recent research on decorporation therapy at National Radiological Protection Board. In: Wrenn ME, ed. Actinides in man and animals. Salt Lake City, UT: University of Utah, RD Press; 1981: 369-379.
232. Stradling GN, Stather JW, Gray SA, Moody JC, Ellender M, Hodgson A. Efficacies of LICAM(C) and DTPA for the decorporation of inhaled transportable forms of plutonium and americium in the rat. Human Toxicol 5:77- 84; 1986.
233. Stradling GN, Stather JW, Gray SA, Moody JC, Ellender M, Hodgson A, Volf V, Taylor DM, Wirth P, Gaskin PW. The efficacies of pure LICAM(C) and DTPA on the retention of plutonium-238 and americium-241 in rats after their inhalation as nitrate and intravenous injection as citrate. Int J Radiat Biol 56:503-514; 1989. (Pubitemid 19248100)
234. Stradling GN, Gray SA, Moody JC, Hodgson A, Raymond KN, Durbin PW, Rodgers SJ, White DL, Turowski PN. The efficacy of DFO-HOPO, DTPA-DX and DTPA for enhancing the excretion of plutonium and americium from the rat. Int J Radiat Biol 59:1269 -1277; 1991a.
235. Stradling GN, Moody JC, Gray SA, Ellender M, Hodgson A. The efficacy of DTPA treatment after deposition of thorium nitrate in the rat lung. Human Exptl Toxicol 10:15-20; 1991b.
236. Stradling GN, Gray SA, Moody JC, Ellender M. Efficacy of tiron for enhancing the excretion of uranium from the rat. Human Exptl Toxicol 10:195-198; 1991c.
237. Stradling GN, Gray SA, Ellender M, Moody JC, Hodgson A, Pearce M, Wilson I, Burgada R, Bailly T, Leroux YPG, ElManouni D, Raymond KN, Durbin PW. The efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat: comparison with other siderophore analogues. Int J Radiat Biol 62:487- 497; 1992.
238. Stradling GN, Gray SA, Ellender M, Pearce M, Wilson I, Moody JC, Hodgson A. Removal of inhaled plutonium and americium from the rat by administration of Zn-DTPA in drinking water. Human Exptl Toxicol 12:233-239; 1993a. (Pubitemid 23162531)
239. Stradling GN, Gray SA, Moody JC, Pearce MJ, Wilson I, Burgada R, Bailly T, Leroux Y, Raymond KN, Durbin PW. Comparative efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat after simulated wound contamination as nitrates. Int J Radiat Biol 64:133-140; 1993b.
240. Stradling GN, Gray SA, Pearce MJ, Wilson I, Moody JC, Burgada R, Durbin PW, Raymond KN. Decorporation of thorium-228 from the rat by 3,4,3-LIHOPO and DTPA after simulated wound contamination. Human Exptl Toxicol 14:165-169; 1995a.
241. Stradling GN, Gray SA, Pearce MJ, Wilson I, Moody JC, Hodgson A, Raymond KN. Efficacy of TREN-(Me-3,2- HOPO), 5-LI(Me-3,2-HOPO) and DTPA for removing plutonium and americium from the rat after inhalation and wound contamination as nitrates. Didcot, Oxfordshire: National Radiological Protection Board; Memo NRPB-M534; 1995b.
242. Stradling GN, Hodgson SA, Pearce MJ. Recent developments in the decorporation of plutonium, americium and thorium. Radiat Prot Dosim 79:445- 448; 1998.
243. Sun PJ, Ferrando Q, Frieser H. Formation constants of transition metal complexes of 2-hydroxypyridine-1-oxide and 2-mercaptopyridine-1-oxide. Anal Chem 36:2485-2488; 1964.
244. Tannenbaum A. Toxicology of uranium. New York: McGraw- Hill Book Co.; 1951.
245. Taylor DM. The effects of desferrioxamine on the retention of actinides in the rat. Health Phys 13:135-140; 1967.
246. Taylor DM. The metabolism of actinium in the rat. Health Phys 19:411- 418; 1970.
247. Taylor DM. Osteosarcoma induction by plutonium-239, americium-241, and neptunium-237: the problem of deriving risk estimates for man. In: Proceedings of the 7th International Conference Internal Radiation Protection Association. London: Pergamon Press; 1988: 162-165.
248. Taylor DM. The biodistribution and toxicity of plutonium, americium, and neptunium. Sci Total Environ 83:217-225; 1989.
249. Taylor DM. Acceleration of the natural rate of elimination of transuranium elements from the mammalian body. In: Freeman AJ, Keller C, eds. Handbook on the physics and chemistry of the actinides, vol 6. Amsterdam: North- Holland; 1991: 533-549.
250. Taylor DM. The bioinorganic chemistry of actinides in the blood. J Alloys Compounds 271-273:6 -10; 1998.
251. Taylor DM, Volf V. Oral chelation treatment of injected 241Am or 239Pu in rats. Health Phys 38:147-158; 1980.
252. Thompson RC. Neptunium-the neglected actinide: a review of the biological and environmental literature. Radiat Res 90:1-32; 1982.
253. Thompson RC. 1976 Hanford americium exposure incident: overview and perspective. Health Phys 45:837- 845; 1983.
254. Thompson RC. Life-span effects of ionizing radiation in the beagle dog. Richland, WA: Pacific Northwest Laboratory; Report PNL-6927; 1989.
255. Turowski PN, Rodgers SJ, Scarrow RC, Raymond KN. Two dihydroxamic derivatives of EDTA and DTPA. Inorg Chem 27:474-481; 1988.
256. Ubios AM, Braun EM, Cabrini RL. Lethality due to uranium poisoning is prevented by ethane-1-hydroxy-1,1- diphosphonate (EHBP). Health Phys 66:540 -544; 1994.
257. Uhlir LC. Mixed functionality sequestering agents. Berkeley, CA: University of California; 1992. Thesis.
258. Van Rossum JP, Schamhart DH. Oxidation-reduction (redox) potentiometry in geriatric conditions: a pilot study. Exptl Gerontol 26:37- 43; 1991.
259. Vaughan J. Distribution, excretion, and effects of plutonium as a bone-seeker. In: Hodge HC, Stannard JN, Hursh JB, eds. New York: Springer-Verlag; 1973: 349-502.
260. Veeck AC, White DJ, Whisenhunt DW, Xu J, Gorden AEV, Romanovski V, Hoffman DC, Raymond KN. Hydroxypyridinone extraction agents for Pu(IV). Solv Extract Ion Exchange 22:1037-1068; 2004.
261. Voegtlin C, Hodge HC. Pharmacology and toxicology of uranium compounds. New York: McGraw-Hill Book Co.; 1949 (vols. 1 and 2), 1953 (vols. 3 and 4).
262. Volf V. Treatment of incorporated transuranium elements. Vienna: IAEA; Technical Report 184; 1978.
263. Volf V. Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFO in rats, hamsters and mice. Int J Radiat Biol 49:449- 462; 1986.
264. Volf V, Wirth R. Effective chelation therapy after incorporation of neptunium-239 in rats. Int J Radiat Biol 50:955-959; 1986. (Pubitemid 17203020)
265. Volf V, Seidel A, Takada K. Comparative effectiveness of Ca-DTPA, desferrioxamine B and their combinations in removing transuranium elements from rats. Health Phys 32:155-157; 1977. (Pubitemid 8075613)
266. Volf V, Taylor DM, Brandau W, Schlenker P. The effect of pure LICAM(C) on the retention of plutonium-238 in mice and rats. Int J Radiat Biol 50:205-211; 1986.
267. Volf V, Burgada R, Raymond KN, Durbin PW. Early therapy for injected Pu-238 an Am-241 in the rat: comparison of 3,4,3-LIHOPO, DFO-HOPO, DTPA-DX and DFOA. Int J Radiat Biol 63:785-793; 1993.
268. Volf V, Burgada R, Raymond KN, Durbin PW. Treatment with 3,4,3-LIHOPO of simulated wounds contaminated with plutonium and americium in the rat. Int J Radiat Biol 70:109 -114; 1996a.
269. Volf V, Burgada R, Raymond KN, Durbin PW. Chelation therapy by DFO-HOPO and 3,4,3-LIHOPO for injected Pu-238 and Am-241 in the rat: effect of dosage, time and mode of chelate administration. Int J Radiat Biol 70:765- 772; 1996b.
270. Weitl FL, Raymond KN. Polycatecholate ligands from 2,3- dihydroxy-5-sulfobenzoyl conjugates of diaza- and tetraazaalkanes. J Am Chem Soc 102:2289 -2293; 1980.
271. Weitl FL, Raymond KN, Smith WL, Howard TR. N,N,N ,N - tetra(2,3-dihydroxybenzoyl) tetraazacyclotetra- and hexadecanes. J Am Chem Soc 100:1170 -1172; 1978.
272. Weitl FL, Raymond KN, Durbin PW. Synthetic enterobactin analogues. Carboxamido-2,3-dihydroxyterephthalate conjugates of spermine and spermidine. J Med Chem 24:203- 205; 1981.
273. White DL, Durbin PW, Jeung N, Raymond KN. Synthesis and initial biological testing of polydentate oxohydroxypyridincarboxylate ligands. J Med Chem 31:11-18; 1988.
274. Wirth JE. Management of exposed personnel. In: Stone RS, ed. Industrial medicine in the plutonium project. New York: McGraw-Hill Book Co.; 1951: 264-275.
275. Wirth R, Volf V. Long-term retention of 237Np in rats. Int J Radiat Biol 46:782-792; 1984.
276. Wirth R, Taylor DM, Duffield J. Identification of transferrin as the principal neptunium-binding protein in the blood serum. Int J Nucl Med Biol 12:327-330; 1985. (Pubitemid 16232481)
277. Wrenn ME. Actinides in man and animals. Salt Lake City, UT: Radiobiology Division, University of Utah, RD Press; 1981.
278. 2+ complexes of linear tetradentate 1-methyl-3-hydroxy-2(1H)-pyridinone ligands. Inorg Chem 38:308 -315; 1999.
279. Xu J, Durbin PW, Kullgren B, Raymond KN. Synthesis and initial evaluation of multidentate 4-carbamoyl-1-3-hydroxy- 1-methyl-2(1H)-pyridinone ligands for in vivo plutonium( IV) chelation. J Med Chem 38:2606 -2614; 1995a.
280. Xu J, Franklin SJ, Whisenhunt Jr. DW, Raymond KN. The gadolinium complex of tris[(3-hydroxy-1-methy1-2-oxo- 1,2-didehydropyridine-4-carboxamino)ethyl] amine: a new class of gadolinium magnetic resonance relaxation agents. J Am Chem Soc 117:7245-7246; 1995b.
281. Xu J, Radkov E, Ziegler M, Raymond KN. Plutonium(IV) sequestration: structure and thermodynamic evaluation of the extraordinarily stable cerium(IV) hydroxypyridinonate complexes. Inorg Chem 39:4156-4164; 2000.
282. Xu J, Durbin PW, Kullgren B, Ebbe SN, Uhlir LC, Raymond KN. Synthesis and initial evaluation for in vivo chelation of Pu(IV) of a mixed 4-carbamoyl-3-hydroxy-1-methy1-2(1H)-pyridinone and 6-carbamoyl-1-hydroxy-2(1H)- pyridinone. J Med Chem 45:3963-3971; 2002.
283. Xu J, Whisenhunt Jr. DW, Veeck AC, Uhlir LC, Raymond KN. Thorium(IV) complexes of bidentate hydroxypyridinonates. Inor Chem 42:2665-2674; 2003.
284. Yuile CL. Animal experiments. In: Hodge HC, Stannard JN, Hursh JB, eds. Uranium, plutonium, transplutonic elements. New York: Springer-Verlag; 1973: 165-196.
285. Zhu D-H, Kappel MJ, Raymond KN. Coordination chemistry of lanthanide catecholates. Inorg Chim Acta 147:115-121; 1988.